ABSTRACT
Objectives We comprehensively characterised a large paediatric cohort with histologically confirmed focal cortical dysplasia (FCD) type 1 to demonstrate the role of advanced multimodal pre-surgical evaluation and identify predictors of postsurgical outcomes.
Methods This study comprised a systematic re-analysis of clinical, electrophysiological, and radiological features. The results of this re-analysis served as independent variables for subsequent statistical analyses of outcome predictors.
Results All children (N = 31) had drug-resistant epilepsy with varying impacts on neurodevelopment and cognition (presurgical intelligence quotient (IQ)/developmental quotient scores: 32–106). Low presurgical IQ was associated with abnormal slow background electroencephalogram (EEG) activity and disrupted sleep architecture. Scalp EEG showed predominantly multiregional and often bilateral epileptiform activity. Advanced epilepsy magnetic resonance imaging (MRI) protocols identified FCD-specific features in 74.2% of patients (23/31), 17 of whom were initially evaluated as MRI-negative. In six out of eight MRI-negative cases, fluorodeoxyglucose positron emission tomography (FDG-PET) and subtraction ictal single-photon emission computed tomography co-registered to MRI (SISCOM) helped localise the dysplastic cortex. Sixteen patients (51.6%) underwent stereoelectroencephalography (SEEG). Twenty-eight underwent resective surgery, and three underwent hemispheral disconnection. Seizure freedom was achieved in 71.0% of patients (22/31) by the last follow-up, including seven of the eight MRI-negative patients. Anti-seizure medications (ASMs) were reduced in 21 patients, with complete withdrawal in 5 individuals. Seizure outcome was predicted by a combination of the following descriptors: age at epilepsy onset, epilepsy duration, long-term invasive EEG, and specific MRI, and PET findings.
Significance This study highlights the broad phenotypic spectrum of FCD type 1, which spans far beyond the narrow descriptions of previous studies. Combining advanced MRI protocols with additional neuroimaging techniques helped localise the epileptogenic zone in many previously non-lesional cases. Complex multimodal presurgical approaches (including SEEG) could enhance postsurgical outcomes in these complex patients.
Key points
The phenotypic spectrum of paediatric patients with FCD type 1 spans beyond the narrow description of previous studies
MRI-negative patients benefit from enhanced precision in localising the epileptogenic zone, facilitated by FDG-PET, SISCOM, and SEEG
A complex multimodal presurgical approach could enhance postoperative seizure outcomes in patients with FCD type 1
Paediatric patients with suspected FCD type 1 should be referred to epilepsy surgery centres as soon as possible
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Ministry of Health of the Czech Republic - grant projects AZV NU23-04-00209, and AZV NU21-08-00228; by Charles University - grant projects GA UK No 94121 and GA UK No 666320, and by project nr. LX22NPO5107 (MEYS): Financed by EU - Next Generation EU. Katerina Mackova was supported by the Grant Agency of the Czech Technical University in Prague (SGS23/170/OHK3/3T/13). Radek Janca was supported by ERDF-Project Brain Dynamics, No. CZ.02.01.01/00/22_008/0004643. The authors thank CESNET for access to their data storage facility. Alice Maulisova and Katerina Bukacova were supported by the Ministry of Health, Czech Republic - conceptual development of research organisation, Motol University Hospital, Prague, Czech Republic 00064203
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional Ethical committee of Motol University Hospital, Prague, Czech Republic (2022/06/15 - EK - 602.24/22)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosures None of the authors has any conflict of interest to disclose.
Funding statement This work was supported by the Ministry of Health of the Czech Republic - grant projects AZV NU23-04-00209, and AZV NU21-08-00228; by Charles University - grant projects GA UK No 94121 and GA UK No 666320, and by project nr. LX22NPO5107 (MEYS): Financed by EU – Next Generation EU. Katerina Mackova was supported by the Grant Agency of the Czech Technical University in Prague (SGS23/170/OHK3/3T/13). Radek Janca was supported by ERDF-Project Brain Dynamics, No. CZ.02.01.01/00/22_008/0004643. The authors thank CESNET for access to their data storage facility. Alice Maulisova and Katerina Bukacova were supported by the Ministry of Health, Czech Republic - conceptual development of research organisation, Motol University Hospital, Prague, Czech Republic 00064203
Study approval statement
Patient consent statement The study was approved by the institutional Ethical committee of Motol University Hospital (2022/06/15 - EK - 602.24/22)
Data availability statement Data that support the findings of this study are available from the corresponding author upon reasonable request.
Ethical publication statement We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
Glossary
- FCD Type 1 / 2
- Focal Cortical Dysplasia Type 1 / 2
- DRE
- Drug Resistant Epilepsy
- ASD
- Autism Spectrum Disorder ASM – Antiseizure Medication
- IEDs
- Interictal Epileptiform Discharges
- MRI
- Magnetic Resonance Imaging
- FDG-PET
- Fluorodeoxyglucose-positron Emission Tomography
- SPECT
- Single Photon Emission Computed Tomography
- VEEG
- Video Electroencephalography
- EEG
- Electroencephalography
- SEEG
- Stereo Electroencephalography
- MOGHE
- mild MCD with Oligodendroglial Hyperplasia and epilepsy
- ILAE
- International League Against Epilepsy
- SISCOM
- Subtraction ictal SPECT coregistered to MRI
- FBTCS
- Focal To Bilateral Tonic-clonic Seizures
- MUHSEC
- Multilobar Unilateral Hypoplasia with Severe Epilepsy in Children
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.